Form 4: CRL CEO Boosts Stake, Achieves Performance Goals

Charles River Laboratories CEO James C. Foster acquired 39,031 shares of common stock through performance awards and disposed of 14,664 shares for tax obligations.

Summary

• James C. Foster, Chairman, President, and CEO of Charles River Laboratories International, Inc. (CRL), reported changes in his beneficial ownership.
• Acquired 39,031 shares of common stock on January 30, 2026, at a price of $0, resulting from the achievement of performance goals for awards originally granted on May 26, 2023.
• Disposed of 14,664 shares of common stock on January 30, 2026, at a price of $211.68, to cover tax liabilities.
• Following these transactions, direct beneficial ownership stands at 253,677 shares.
• Indirect holdings include 5,423 shares in a 2024 GRAT, 20,000 shares in a 2025 GRAT, 3,230 shares across various trusts, and 10,000 shares held by spouse.
• Exempt transfers under Rule 16a-13 included 14,577 shares from the 2024 GRAT account and 4,048 shares from the 2022 GRAT account to direct holdings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, primarily because the CEO achieved performance goals, leading to a significant share acquisition, which reflects positively on company operational success. The subsequent tax-related sale is a standard practice.

Positives

• CEO James C. Foster achieved performance goals, leading to the issuance of 39,031 shares of common stock.
• The acquisition of shares through performance awards indicates successful execution against company objectives.

Negatives

• Disposition of 14,664 shares to cover tax liabilities, which is a common practice but reduces direct ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving performance-based awards, can signal management confidence in future company performance within the pharmaceutical services and biotechnology support industry. The tax-related disposition is a routine event.

Comparison to Industry Standards

• Performance-based equity awards are a standard compensation practice for executives in the life sciences and contract research organization (CRO) sectors, aligning executive incentives with shareholder value.
• The disposition of shares to cover tax liabilities upon vesting of equity awards is a common and expected practice among executives across all industries, including peers like LabCorp (LH) or IQVIA (IQV).

Related Party Transactions

• Transfer of 14,577 shares from the 2024 GRAT account to direct holdings.
• Transfer of 4,048 shares from the 2022 GRAT account to direct holdings.
• Indirect beneficial ownership includes 5,423 shares in 2024 GRAT, 20,000 shares in 2025 GRAT, 3,230 shares across various trusts, and 10,000 shares held by spouse.

Stakeholder Impact

• Shareholders: The CEO's increased direct ownership (net of tax sales) and achievement of performance goals could be seen as a positive indicator of management alignment and company performance.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions where the CEO received shares for achieving performance goals and subsequently sold a portion to cover tax obligations. While the achievement of performance goals is positive, these transactions are expected and do not introduce new material information that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Charles River Laboratories, CRL, James C. Foster, Insider Trading, Form 4, Stock Ownership, Performance Shares, CEO, Biotechnology, Pharmaceutical Services